AI-Enabled Drug Discovery is on the verge of a new revolution, with the first data emerging from exciting research indicating ...
The groundbreaking results of the OVATION 2 Study demonstrated a substantial 35% improvement in overall survival, equating to ...
The US Food and Drug Administration (FDA) has granted accelerated approval to Ziihera (zanidatamab-hrii), a novel therapy for ...
ONCOLife proudly presents an exclusive interview with Dr. Iris Kuss, VP and Global Development Lead Oncology at Bayer. In ...
The U.S. Food and Drug Administration (FDA) has approved revumenib, a pioneering drug for relapsed or refractory acute ...
Oncolytic viruses are a very promising class of therapeutic agents, with a broad range of types. In this exclusive interview ...
Researchers from Cambridge University Hospitals, in collaboration with the NHS Health Research Authority, have launched the ...
IMUNON’s Phase 2 OVATION 2 study shows promising results for its immunotherapy, IMNN-001, in advanced ovarian cancer. Combined with standard chemotherapy, IMNN-001 improved overall survival by 35% and ...
Cytokine therapies have the potential to transform cancer treatment by enhancing the body’s immune response to fight cancer more effectively. In our interview with Caroline Loew, Ph.D., CEO of Mural ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback